« Think Twice |
| Ancient Metals »
March 17, 2005
Symlin, At Last
I wanted to take a moment to congratulate Amylin on the FDA approval of their diabetes therapy Symlin. I've known a couple of people out there over the years. Actually, a lot of people have had a chance to know someone at Amylin, because the company has had more than one near-death experience, during which they've had to fire big swaths of their staff. A couple of years later, they'd start hiring again, until the next safe landed on top of them. I'd like to know just how many employees have been with them for more than ten years - you could probably count them on one hand.
As this look back at the Motley Fool mentions, the drug has been through six Phase III trials over the years. That's a level of perseverance that borders on the pathological. You could only get away with this with a biological product, where the barrier to going generic is so high. A small molecule would have about ten minutes left on its patent by now, and its value would be much lower (which gets back to that Forbes column about patent extensions, actually.)
Here's a multiyear chart of Amylin's stock, so you can vicariously experience the thrills yourself.
+ TrackBacks (0) | Category: Diabetes and Obesity
- RELATED ENTRIES
- Scripps Update
- What If Drug Patents Were Written Like Software Patents?
- Stem Cells: The Center of "Right to Try"
- Speaking of Polyphenols. . .
- Dark Biology And Small Molecules
- How Polyphenols Work, Perhaps?
- More On Automated Medicinal Chemistry
- Scripps Merging With USC?